KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares IssuedShares OutstandingShares Repurchased
Ratios

Sarepta Therapeutics (SRPT) Long-Term Debt Repayments: 2011-2018

Historic Long-Term Debt Repayments for Sarepta Therapeutics (SRPT) over the last 8 years, with Dec 2018 value amounting to $17.3 million.

  • Sarepta Therapeutics' Long-Term Debt Repayments rose 4.12% to $17.3 million in Q4 2018 from the same period last year, while for Dec 2018 it was $236.0 million, marking a year-over-year increase of 495.17%. This contributed to the annual value of $550.0 million for FY2022, which is N/A change from last year.
  • Per Sarepta Therapeutics' latest filing, its Long-Term Debt Repayments stood at $17.3 million for Q4 2018, which was down 61.49% from $45.0 million recorded in Q3 2018.
  • Over the past 5 years, Sarepta Therapeutics' Long-Term Debt Repayments peaked at $100.1 million during Q1 2018, and registered a low of -$2.5 million during Q4 2016.
  • Its 3-year average for Long-Term Debt Repayments is $23.2 million, with a median of $10.8 million in 2017.
  • In the last 5 years, Sarepta Therapeutics' Long-Term Debt Repayments crashed by 9,992.00% in 2016 and then surged by 232,788.37% in 2018.
  • Sarepta Therapeutics' Long-Term Debt Repayments (Quarterly) stood at $23,000 in 2014, then surged by 10,873.91% to $25,000 in 2015, then slumped by 9,992.00% to -$2.5 million in 2016, then surged by 772.75% to $16.6 million in 2017, then grew by 4.12% to $17.3 million in 2018.
  • Its last three reported values are $17.3 million in Q4 2018, $45.0 million for Q3 2018, and $73.5 million during Q2 2018.